Roivant Sciences
Develops immunology medicines and delivery technologies through focused Vant subsidiaries.
$34.44
After-hours close−0.25 (−0.72%)
At close$34.69(−7.69%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.41 | — | — |
| Aug 2026 | −$0.30 | −$0.33 | −10.1% |
| Jul 2026 | −$0.29 | — | — |
| May 2026 | −$0.29 | −$0.28 | +3.5% |
| Feb 2026 | −$0.30 | −$0.24 | +19.9% |
| Nov 2025 | −$0.32 | −$0.28 | +12.4% |
The latest year is open to everyone — the 18 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| Jun 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Jun 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Sep 2021 | — | — | — |
| Aug 2021 | — | — | — |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.41 | — | — | $3.9M | — | — |
| Aug 6, 2026 | −$0.30 | −$0.33 | −10.1% | $2.1M | $1.4M | −29.9% |
| Jul 1, 2026 | −$0.29 | — | — | $3.8M | — | — |
| May 20, 2026 | −$0.29 | −$0.28 | +3.5% | $3.4M | $2.5M | −26.2% |
| Feb 6, 2026 | −$0.30 | −$0.24 | +19.9% | $5.1M | $2.0M | −60.6% |
| Nov 10, 2025 | −$0.32 | −$0.28 | +12.4% | $5.6M | $1.6M | −72.0% |
The latest year is open to everyone — the 18 quarters behind it read with an account. Sign in | ||||||
| Aug 11, 2025 | ||||||
| May 29, 2025 | ||||||
| Feb 10, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 30, 2024 | ||||||
| Feb 13, 2024 | ||||||
| Nov 13, 2023 | ||||||
| Aug 14, 2023 | ||||||
| Jun 28, 2023 | ||||||
| Feb 13, 2023 | ||||||
| Nov 14, 2022 | ||||||
| Aug 15, 2022 | ||||||
| Jun 28, 2022 | ||||||
| Feb 14, 2022 | ||||||
| Nov 15, 2021 | ||||||
| Sep 21, 2021 | — | — | — | — | — | — |
| Aug 10, 2021 | — | — | — | — | — | — |